Johnson & Johnson (NYSE:JNJ): Applications for two separate drugs that are intended to extend the use of Zytiga, were submitted to agencies simultaneously. Janssen-Cilag reports that it submitted a type II variation to the European Medicines Agency for Zytiga, and Janssen Research & Development submitted a supplemental New Drug Application to the FDA. Both applications are meant to extend the use of Zytiga administered with prednisone for the treatment of patients with metastatic castration resistant prostate cancer, who are asymptomatic or mildly symptomatic following the failure of androgen deprivation therapy but prior to chemotherapy.
Don’t Miss: Will RIM Strike GOLD With This New Product?
JPMorgan Chase & Co. (NYSE:JPM) continues in the investors spotlight after CEO Jamie Dimon admitted “We made a mistake. I’m absolutely responsible. The buck stops with me”, told a Congressional banking panel that the JPM officers responsible for The Loss will ‘most likely have some of their pay taken away’.
Microsoft Corporation’s (NASDAQ:MSFT) mobile aspirations could be significantly threatened by the current implosion of Nokia (NYSE:NOK), since the firms partnered closely in 2011 in a desperate effort to compete in a smartphone market that is dominated by Apple (NASDAQ:AAPL) and Google (NASDAQ:GOOG), says a Wall Street Journal report.
United Technologies Corporation’s (NYSE:UTX) $16.5 billion acquisition of aircraft parts producer Goodrich Corporation (NYSE:GR), has won conditional approval by China’s Commerce Ministry, but the regulator also remarked that the latter should divest or sell parts of some of its businesses, according to Reuters. The takeover is also being evaluated by the European Commission.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.